Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Ann Arbor, Michigan 48109


The purpose of this study is to compare the liver stiffness, which can be caused by congestion and fibrosis in pediatric patients before and after a Fontan heart operation. A new form of ultrasound elastography (Acoustic Radiation Force Impulse, or ARFI) will measure liver stiffness.

Study summary:

The Fontan repair for single ventricle congenital heart lesions consists of three stages. This surgery has enable pediatric patients who have the repair to live into adulthood. Stage 3 of the surgery introduces immediate congestion of blood in the liver by increasing central venous pressure (CVP). CVP is the blood pressure within the vena cava, a major blood vessel in the body. Many patients later develop progressive liver fibrosis (stiffness) possibly as a result of increased blood pressure. Liver stiffness is increased both by congestion and fibrosis. Liver fibrosis has significant health risks and may complicate the patient's future healthcare. There are no established, noninvasive means of detecting the liver fibrosis until it becomes severe. Acoustic radiation force impulse (ARFI) elastography, an ultrasound technique, can measure the stiffness of the liver safely from outside the body. The investigators hypothesize that liver stiffness will be increased by stage 3 of the Fontan operation due to onset of liver congestion. Using ARFI, the investigators will measure liver stiffness before and immediately after stage 3 of the Fontan operation, when congestion of blood is likely the only contributor to any change in liver stiffness. The investigators will follow the trend of liver stiffness at six months by repeating the ARFI imaging.


Inclusion Criteria: - Pediatric patients ages 0-17 - Patients presenting to the University of Michigan for evaluation just before undergoing stage 3 of the Fontan operation Exclusion Criteria: - Patients over the age of 17 - Patients who have chronic liver disease (elevation of ALT, AST, or Bilirubin greater than two times the upper limits of normal >4 weeks) - Patients who have evidence of liver enlargement or nodularity on prior ultrasound imaging - Patients who have a history of portal vein or hepatic vein thrombosis - Patients (parents) who are unwilling to read and sign the informed consent document



Primary Contact:

Principal Investigator
Frank W DiPaola, MD
University of Michigan

Backup Contact:


Location Contact:

Ann Arbor, Michigan 48109
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.